Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Thoracic Malignancies
•
Medical Oncology
Do you utilize consolidative radiation for metastatic NSCLC lung cancer patients on maintenance immunotherapy?
Or do you reserve in case of oligo-progression or progressive/symptomatic disease?
Answer from: Medical Oncologist at Community Practice
Yes but please refer these patients for NRG-LU002 study which is directly addressing this important question.
Sign In
or
Register
to read more
5515
Related Questions
How would you respond to a patient with early-stage resectable NSCLC who has a clinical complete response to neoadjuvant chemo-IO, but subsequently declines surgery, not feeling it's necessary anymore?
In stage IV oligometastatic NSCLC, when considering local consolidative therapies to the primary tumor, do providers typically stage the mediastinum at diagnosis or after initial systemic therapy (assuming no progression)?
Would a patient with a resected NSCLC mass under 3 cm, without lymph node involvement or distant metastases, but with visceral invasion identified on pathology, benefit from adjuvant therapy?
Can Dupixent and Durvalumab be used at the same time in a patient with extensive stage small cell lung cancer?
How, if at all, are you modifying your practice and clinical workflow for patients receiving checkpoint inhibitors with data showing improved outcomes for patients receiving infusions earlier in the day?
How would you treat patient with a stage IV lung adenocarcinoma, an exon 21 p.H835L mutation, high TMB, and negative PD-L1?
Would you give adjuvant sunvozertinib to patients with stage II-III NSCLC with an EGFR exon 20 insertion mutation?
Is there a biomarker for which patients benefit from tarlatamab?
What are the main practical factors to consider when using bispecific antibody therapy (Tarlatamab) for extensive-stage small cell lung cancer?
How would you treat a patient with metastatic NSCLC, adenocarcinoma subtype with BRAF V600K mutation, PD-L1 >50% with progression on 1st line chemo-immunotherapy?